JP Morgan Chase’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-206,223
| Closed | -$21M | – | 7817 |
|
|
2023
Q2 | $21M | Buy |
206,223
+82,980
| +67% | +$7.85M | ﹤0.01% | 1664 |
|
|
2023
Q1 | $11.2M | Sell |
123,243
-44,173
| -26% | -$2.59M | ﹤0.01% | 2177 |
|
|
2022
Q4 | $6.36M | Buy |
167,416
+34,356
| +26% | +$1.18M | ﹤0.01% | 2630 |
|
|
2022
Q3 | $3.35M | Buy |
133,060
+88,750
| +200% | +$2.46M | ﹤0.01% | 3068 |
|
|
2022
Q2 | $1.35M | Buy |
44,310
+16,148
| +57% | +$482K | ﹤0.01% | 3865 |
|
|
2022
Q1 | $923K | Buy |
28,162
+4,398
| +19% | +$131K | ﹤0.01% | 4334 |
|
|
2021
Q4 | $627K | Sell |
23,764
-2,273
| -9% | -$176K | ﹤0.01% | 4690 |
|
|
2021
Q3 | $2.62M | Buy |
26,037
+1,242
| +5% | +$146K | ﹤0.01% | 3560 |
|
|
2021
Q2 | $3.51M | Sell |
24,795
-12,285
| -33% | -$1.39M | ﹤0.01% | 3350 |
|
|
2021
Q1 | $3.7M | Sell |
37,080
-3,854
| -9% | -$450K | ﹤0.01% | 3228 |
|
|
2020
Q4 | $5.06M | Buy |
40,934
+4,340
| +12% | +$570K | ﹤0.01% | 2806 |
|
|
2020
Q3 | $3.47M | Sell |
36,594
-5,141
| -12% | -$642K | ﹤0.01% | 2853 |
|
|
2020
Q2 | $6.51M | Sell |
41,735
-413
| -1% | -$62.8K | ﹤0.01% | 2253 |
|
|
2020
Q1 | $6.08M | Sell |
42,148
-13,192
| -24% | -$2.55M | ﹤0.01% | 2105 |
|
|
2019
Q4 | $11.3M | Sell |
55,340
-2,608
| -5% | -$476K | ﹤0.01% | 2019 |
|
|
2019
Q3 | $4.65M | Buy |
57,948
+3,118
| +6% | +$265K | ﹤0.01% | 2752 |
|
|
2019
Q2 | $5.02M | Sell |
54,830
-2,794
| -5% | -$241K | ﹤0.01% | 2653 |
|
|
2019
Q1 | $4.92M | Sell |
57,624
-27,634
| -32% | -$2.29M | ﹤0.01% | 2597 |
|
|
2018
Q4 | $4.78M | Sell |
85,258
-38,414
| -31% | -$2.35M | ﹤0.01% | 2600 |
|
|
2018
Q3 | $10.1M | Sell |
123,672
-26,316
| -18% | -$1.85M | ﹤0.01% | 2203 |
|
|
2018
Q2 | $5.24M | Sell |
149,988
-18,774
| -11% | -$572K | ﹤0.01% | 2653 |
|
|
2018
Q1 | $3.46M | Sell |
168,762
-55,392
| -25% | -$1.43M | ﹤0.01% | 2873 |
|
|
2017
Q4 | $6.35M | Sell |
224,154
-4,458
| -2% | -$124K | ﹤0.01% | 2476 |
|
|
2017
Q3 | $7.11M | Sell |
228,612
-3,950
| -2% | -$119K | ﹤0.01% | 2278 |
|
|
2017
Q2 | $7.36M | Buy |
232,562
+101,969
| +78% | +$2.51M | ﹤0.01% | 2197 |
|
|
2017
Q1 | $2.96M | Sell |
130,593
-14,500
| -10% | -$358K | ﹤0.01% | 2797 |
|
|
2016
Q4 | $3.17M | Buy |
145,093
+4,415
| +3% | +$112K | ﹤0.01% | 2786 |
|
|
2016
Q3 | $3.71M | Sell |
140,678
-102,300
| -42% | -$2.03M | ﹤0.01% | 2437 |
|
|
2016
Q2 | $4.8M | Buy |
+242,978
| New | +$4.72M | ﹤0.01% | 2319 |
|
Other funds holding RETA
JP Morgan Chase's RETA Position: Q3 2023 in Review
JP Morgan Chase sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 206,223 shares — an estimated $21M sold.
JP Morgan Chase first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $21M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- JP Morgan Chase reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- JP Morgan Chase sold 206,223 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $21M.
- JP Morgan Chase first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- JP Morgan Chase's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $21M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.